46 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
25
Ending by 2030
Apr 2027
Next term end
21
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2032 · High confidence
Also notable
Ends Apr 2027 · High confidence
Also notable
Ends Feb 2028 · High confidence
VEGF/DLL4 Binding Agents and Uses Thereof
US 8,858,941
Cited by 48 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Compositions and Methods for Inhibiting Wnt-Dependent Solid Tumor Cell Growth
US 7,723,477
Cited by 63 later US patents, top 25% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Antibodies to Notch Receptors
US 7,919,092
Cited by 55 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 26, 2026The maintenance fee for Compositions and Methods for Treating and Diagnosing Cancer (US 9,040,044) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
- 1 fee due Dec 30, 2026The maintenance fee for Method for Making Heteromultimeric Molecules (US 9,067,986) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Apr 13, 2027The maintenance fee for WNT Antagonists and Methods of Treatment and Screening (US 9,157,904) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Tigit-Binding Agents and Uses Thereof (US 10,544,219) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Monoclonal Antibodies Against Frizzled (US 9,273,139) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Oct 12, 2027The maintenance fee for Method for Making Heteromultimeric Molecules (US 9,309,311) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
- 4 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 21 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| VEGF/DLL4 Binding Agents and Uses Thereof | 6 in force | to Sep 2032 |
| Compositions and Methods for Treating and Diagnosing Cancer | 4 in force | to Jul 2028 |
| Antibodies to Notch Receptors | 4 in force | to Feb 2028 |
| Method for Making Heteromultimeric Molecules | 3 in force | to Nov 2031 |
| Methods of Treatment with DLL4 Antagonists and an Anti-Hypertensive Agent | 3 in force | to Nov 2030 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,723,477 | Compositions and Methods for Inhibiting Wnt-Dependent Solid Tumor Cell Growth In force · High confidence | In force | High confidence | |
| US 8,206,713 | Method of Treating Cancer Using Antibodies to a Non-Ligand Binding Region of NOTCH2 In force · High confidence | In force | High confidence | |
| US 8,404,237 | Antibodies to the NOTCH1 Receptor In force · High confidence | In force | High confidence | |
| US 9,676,865 | Antibodies to a Non-Ligand Binding Region of at Least Two Notch Receptors In force · Medium confidence | In force | Medium confidence | |
| US 9,228,020 | Compositions and Methods for Diagnosing and Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 7,919,092 | Antibodies to Notch Receptors In force · High confidence | In force | High confidence | |
| US 7,750,124 | Anti-Human DLL4 Antibodies and Compositions In force · High confidence | In force | High confidence | |
| US 9,376,497 | Compositions and Methods for Diagnosing and Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 8,158,758 | Compositions and Methods for Treating and Diagnosing Cancer In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence | |
| US 8,540,989 | Compositions and Methods for Treating and Diagnosing Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 46: 2 patents in force now held by others · 8 patents ended · 1 application pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.